Bridgeway Capital Management’s Kyverna Therapeutics KYTX Stock Holding History

Bridgeway Capital Management’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.29M	Sell	149,900 -25,000	-14%	-$208K	0.03%	646
2025 Q4	$1.64M	Hold	174,900	–	–	0.03%	595
2025 Q3	$1.05M	Buy	174,900 +112,000	+178%	+$448K	0.02%	690
2025 Q2	$193K	Sell	62,900 -73,400	-54%	-$182K	﹤0.01%	969
2025 Q1	$263K	Buy	136,300 +56,300	+70%	+$166K	0.01%	864
2024 Q4	$299K	Buy	+80,000	New	+$383K	0.01%	923

Other funds holding KYTX

GGI

GordonMD Global Investments Beverely Hills, California $144M AUM

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Bridgeway Capital Management's KYTX Position: Q1 2026 in Review

Bridgeway Capital Management reduced its Kyverna Therapeutics (KYTX) stake by 14% in Q1 2026, selling an estimated $208K and leaving 149,900 shares worth $1.29M. The position accounts for 0.03% of the portfolio, ranked #646.

Bridgeway Capital Management first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.64M in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

Bridgeway Capital Management held 149,900 shares of Kyverna Therapeutics worth $1.29M as of Q1 2026.
Bridgeway Capital Management sold 25,000 Kyverna Therapeutics shares in Q1 2026, an estimated $208K.
Kyverna Therapeutics made up 0.03% of Bridgeway Capital Management's portfolio in Q1 2026, its #646 holding.
Bridgeway Capital Management first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
Bridgeway Capital Management's Kyverna Therapeutics position peaked at $1.64M in Q4 2025.
111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.